Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23452086 | 0.88 | CA1 (0.49) | MAPTKMT2AL3MBTL1MEN1TDP1 | |
| SCHEMBL612035 | 0.86 | POLB (0.49) | MAPTRAB9AKMT2AL3MBTL1POLB | |
| SCHEMBL1458598 | 0.79 | KDM4E (0.47) | MAPTRAB9ANPC1KMT2AL3MBTL1 | |
| SCHEMBL614635 | 0.79 | KDM4E (0.50) | RAB9AKMT2AMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL613592 | 0.79 | KDM4E (0.40) | RAF1MAPTMAPK14KMT2AL3MBTL1 | |
| SCHEMBL611970 | 0.77 | MEN1 (0.55) | MAPTRAB9ANPC1KMT2AL3MBTL1 | |
| SCHEMBL614632 | 0.75 | MAPT (0.52) | MAPTRAB9ANPC1KMT2AMEN1 | |
| SCHEMBL612156 | 0.75 | MAPT (0.42) | RAF1MAPTMAPK14KMT2AL3MBTL1 | |
| SCHEMBL613554 | 0.74 | PPARG (0.36) | RAF1MAPTMAPK14KMT2AL3MBTL1 | |
| SCHEMBL21411362 | 0.71 | ALDH1A1 (0.58) | RAF1MAPTMAPK14L3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2480556-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2012-08-01 | — | — | EP | disclosed |
| WO-2011036128-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | WO | disclosed |
| US-20110070190-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ROCHE PALO ALTO LLC (US) | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110070190-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | EIF2AK2, RTF2, HCCS | RAF1 2504/4885MAPT 4705/4885MAPK14 3562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.